In conclusion, we believe that intervention in the interaction between RIG‐I‐MAVS signaling and SARS‐CoV‐2 viral proteins or activation of RIG‐I‐MAVS signaling is a potential therapeutic strategy against viral infection and replication. The gene discussed is MAVS; the disease is viral infectious disease.